Both the companies have not disclosed the financial terms of the agreement.
Genmab chief executive officer Jan van de Winkel said the company is happy to enter its first research collaboration for the HexaBody technology which was unveiled just over a year ago.
"This exciting technology has the potential to enhance antibody efficacy in a fundamentally new way," van de Winkel said.
"We are also very pleased to enter another DuoBody platform collaboration and we look forward to exploring the therapeutic potential of products incorporating the HexaBody and DuoBody technologies with this major Biotechnology company."
DuoBody platform is used to discover and develop bispecific antibodies that may improve antibody therapy of cancer, autoimmune, infectious and central nervous system disease.
Genmab’s broadly applicable antibody platform from ‘HexaBody technology’ helps in the creation of potent therapeutics by inducing antibody hexamer formation (clusters of six antibodies).